II. Indications

III. Dosing: Adults

  1. Start 2.5 mg orally twice daily
  2. Target: 5 to 10 mg/day divided twice daily
  3. Maximum: 20 mg/day (10 mg/day in the elderly)

IV. Mechanism

  1. See Dihydropyridine Calcium Channel Blocker
  2. Selectively inhibits vascular smooth Muscle Contraction and SA Node conduction
  3. Does not reduce cardiac contractility
  4. Does not affect AV Node conduction

V. Adverse Effects

  1. See Dihydropyridine Calcium Channel Blocker
  2. Less reflex Tachycardia than other agents due to selectivity
  3. Headache
  4. Peripheral Edema
  5. Flushing

VI. Safety

  1. Pregnancy Category C
  2. Unknown Safety in Lactation

VII. Metabolism

  1. Well absorbed, but high first pass metabolism

IX. References

  1. (2022) Presc Lett, Resource #381108, Comparison of Calcium Channel Blockers
  2. (2020) Med Lett Drugs Ther 62(1598): 73-80
  3. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 70-1
  4. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Isradipine (C0071304)

Definition (MSH) A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Definition (NCI) A dihydropyridine calcium channel blockers with antihypertensive and vasodilator activities. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decrease in total peripheral resistance. (NCI05)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D017275
SnomedCT 108533002, 386862002
English Isradipine, 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, 3,5-Pyridinedicarboxylic Acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, Methyl 1-methylethyl Ester, Isopropyl methyl(+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, isradipine (medication), isradipine, ISRADIPINE, Isradipine [Chemical/Ingredient], Isradipine (product), Isradipine (substance)
Swedish Isradipin
Czech isradipin
Finnish Isradipiini
Russian IZRADIPIN, ИЗРАДИПИН
Japanese イスラジピン
Spanish isradipino (sustancia), isradipino (producto), isradipino, isradipina, isradipina (producto), isradipina (sustancia), Isradipino
Polish Isradypina
French Isradipine
German Isradipin
Italian Isradipina
Portuguese Isradipino

Ontology: Dynacirc (C0813618)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D017275
English dynacirc, Dynacirc